A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

NCT06586112 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

912

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Envudeucitinib
DRUG: Apremilast
DRUG: Placebo

Sponsor

Alumis Inc